CD274 and non-small cell lung carcinoma: The first US Food and Drug Administration approval for 1L treatment of NSCLC with an IO agent was granted in October 2016 for pembrolizumab monotherapy in patients whose tumor cell PD-L1 expression was ≥ 50% (Pai-Scherf et al. 2017).